歸創通橋-B:年報 2023
Guichuang Tongqiao-B (02190) bought back 4000 shares on April 17
Guichuang Tongqiao-B (02190) announced that on April 17, 2024, the company spent HK$38,000...
Guichuang Tongqiao-B (02190.HK) spent HK$933,000 to buy back 104,000 shares on April 16
Gelonghui, April 16 | Guichuang Tongqiao-B (02190.HK) announced that it spent HK$933,000 to repurchase 104,000 shares on April 16, at a price of HK$8.78-9.09 per share.
The results for the full year of 2023 were announced. What was the performance of innovative medical device companies under the collection test?
Hengqiang, the strongest in innovative medical devices
Guichuang Tongqiao-B (02190.HK): The State Drug Administration approved the launch of the Tongqiao Kirin blood flow guide device
On March 25, Gelonghui | Guichuang Tongqiao-B (02190.HK) announced that the Tongqiao Kirin blood flow guidance device independently developed by the Group has been approved for listing by the China Drug Administration (“State Drug Administration”). As the first fully developed remote closed dense mesh stent made in China, the Tsuqiao Kirin blood flow guide device will not only bring new treatment options for intracranial aneurysm treatment; at the same time, it will further enrich the company's product portfolio matrix and enhance the company's influence in the field of neurovascular interventional treatment in China. As of the date of this announcement, the company has obtained approval from the State Drug Administration for a total of 41 products in China. According to the disclosure, blood
Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023
Zylox-Tonbridge Medical Technology (HKG:2190) recorded a 30.7% decline in attributable loss for the year ended Dec. 31, 2023, to 78.7 million yuan from 113.6 million yuan in 2022, a Friday filing on t
Press Release: Zylox-Tonbridge Announces Annual Financial Results for 2023, Demonstrating Robust Growth and Improved Profitability
HANGZHOU, China, March 22, 2024 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial results for 2023.
Guichuang Tongqiao (02190) has excellent results in 2023: operating revenue increased 58% to 530 million yuan to achieve profit under the adjusted net profit scale
Along with the expansion of revenue scale and overall improvement in operating efficiency, Guichuang Tongqiao achieved an adjusted net profit of 7.03 million yuan in 2023.
ZYLOXTB-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Guichuang Tongqiao-B (02190.HK) plans to hold a board meeting on March 21 to approve the annual results
Gelonghui March 8 | Guichuang Tongqiao-B (02190.HK) announced that the company will hold a board meeting on March 21, 2024 (Thursday) to review and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to deal with other matters.
歸創通橋-B:董事會會議通告
Avinger Shares Jump Premarket on Zylox-Tonbridge Partnership
By Colin Kellaher Shares of Avinger rose more than 15% in premarket trading Thursday after the medical-device company said it formed a partnership with China's Zylox-Tonbridge Medical Technology tha
Zylox-Tonbridge Enters Licensing, Investment Contracts With American Innovative Medical Device Maker
Zylox-Tonbridge Medical Technology (HKG:2190) has entered into several licensing and investment agreements with US-based innovative medical device firm Avinger to improve its peripheral-vascular inter
Changes in Hong Kong stocks | Guichuang Tongqiao-B (02190) rose more than 4% to obtain exclusive rights from Avinger Peripheral Vascular Interventional Devices Group in Greater China
Guichuang Tongqiao-B (02190) is now up more than 4%. As of press release, it is up 4.52% to HK$9.95, with a turnover of HK$1,819,300.
Guichuang Tongqiao-B (02190.HK) signs licensing and investment agreement with AVINGER INC.
Guichuang Tongqiao-B (02190.HK) announced that in order to enhance the company's peripheral vascular intervention device portfolio, the company has entered into a series of licensing and investment agreements with Avinger Inc. (“Avinger”). Avinger is an American innovative medical device company and an independent third party.
Guichuang Tongqiao-B (02190) signs licensing and investment agreement with AVINGER INC.
Guichuang Tongqiao-B (02190) announced that in order to enhance the company's peripheral vascular intervention device portfolio, the company has entered into a series of licensing and investment agreements with Avinger Inc. (Avinger). Avinger is an American innovative medical device company and a third party independent of the company and its affiliates.
Gichuang Medical's ZYLOX Penguin static to iliac stent system was approved for marketing by NMPA
On January 22, Guichuang Tongqiao (2190.HK, hereinafter referred to as the “Company”) announced that the ZYLOX Penguin Jingji iliac stent system independently developed by Guichuang Medical has been approved for marketing by the National Drug Administration (NMPA). This marks another milestone in Guichuang Medical's overall solution for peripheral venous disease interventional treatment, and further consolidates its market position and influence in the field of peripheral vascular intervention. The ZYLOX Penguin Iliac Stent System is an innovative medical engineering combination product developed by Guichuang Medical in collaboration with well-known domestic experts. This product
China Grants Marketing Approval to Zylox-Tonbridge's Peripheral Venous Stent System; Shares Fall 7%
China's medical products administrator granted marketing approval to Zylox-Tonbridge Medical Technology's (HKG:2190) Penguin peripheral venous stent system for peripheral venous diseases, a Monday fil
Guichuang Tongqiao (02190): The State Drug Administration approved the launch of the ZYLOX Penguin static to iliac stent system
Jinwu Financial News | Guichuang Tongqiao (02190) announced that the ZYLOX Penguin static to iliac stent system independently developed by the Group has been approved for listing by the National Drug Administration (NMPA). This marks another landmark advance in the company's overall solution for interventional treatment of peripheral venous disease, and further consolidates its market position and influence in the field of peripheral vascular intervention. As of the date of this announcement, the company has obtained approval from the State Drug Administration for a total of 36 products in China. The ZYLOX Penguin Iliac Stent System is operated by the Group and the First Affiliated Hospital of Chongqing Medical University
We Might See A Profit From Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) future prospects.
No Data